Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04196491
Recruitment Status : Recruiting
First Posted : December 12, 2019
Last Update Posted : September 16, 2020
Sponsor:
Information provided by (Responsible Party):
Celgene

Brief Summary:
This is a multicenter, open-label, phase 1, single arm study intended to determine the optimal target dose and safety of bb2121 in subjects with HR (R-ISS Stage III per IMWG criteria) NDMM. Subjects should have received 3 Cycles of standard induction therapy prior to undergoing leukapheresis procedure to collect autologous mononuclear cells for manufacture of the drug product (bb2121). Following manufacture of the drug product, subjects will receive fourth cycle of induction therapy followed by lymphodepleting therapy with fludarabine and cyclophosphamide prior to bb2121 infusion. Maintenance therapy is recommended for all subjects who have received bb2121 infusion and should be initiated upon adequate bone marrow recovery or from 90-day post-bb2121 infusion, whichever is later.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Biological: bb2121 carfilzomib Drug: Fludarabine Drug: Cyclophosphamide Drug: Lenalidomide Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4)
Actual Study Start Date : May 27, 2020
Estimated Primary Completion Date : January 15, 2025
Estimated Study Completion Date : January 15, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: Dose Escalation
  • bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 800 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy with a planned starting dose of 450 x 10^6 CAR+ T cells.
  • Lenalidomide maintenance therapy is recommended for all patients and should be initiated upon adequate bone marrow recovery or from 90-day post-bb2121 infusion, whichever is later
Biological: bb2121 carfilzomib
CAR-T Cell Therapy
Other Name: ide-cel

Drug: Fludarabine
Lymphodepleting Chemotherapy

Drug: Cyclophosphamide
Lymphodepleting Chemotherapy

Drug: Lenalidomide
Maintenance Therapy




Primary Outcome Measures :
  1. Dose-limiting toxicity (DLT) rates [ Time Frame: Up to approximately 2 years after first subject bb2121 infused ]
    DLTs will be assessed during the DLT interval (ie, within 21 days immediately after bb2121 infusion). DLTs are defined as any bb2121 related Grade 3 to 5 toxicity.

  2. Adverse Events (AEs) [ Time Frame: Up to approximately 5 years after first subject bb2121 infused ]
    An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.


Secondary Outcome Measures :
  1. Proportion of subjects who achieved Complete Response (CR) Rate [ Time Frame: Approximately 2.5 years after first subject bb2121 infused ]
    Is defined as proportion of subjects who achieved CR or better according to IMWG Uniform Response Criteria for Multiple Myeloma for multiple myeloma will be determined by an Investigator assessment.

  2. Overall Response Rate (ORR) [ Time Frame: Approximately 2.5 years after first subject bb2121 infused ]
    Is defined as proportion of subjects who achieved PR or better according to IMWG Uniform Response Criteria for Multiple Myeloma as determined by an Investigator assessment

  3. Duration of Response (DoR) [ Time Frame: Approximately 2.5 years after first subject bb2121 infused ]
    Is defined as time from first documentation of response (PR or better) to first documentation of progressive disease (PD) or death from any cause, whichever occurs first, for responders.

  4. Time to Complete Response (TCR) [ Time Frame: Approximately 2.5 years after first subject bb2121 infused ]
    Is defined as time from bb2121 infusion date to first documentation of CR for responders (Complete Response (CR) or better).

  5. Time to start maintenance [ Time Frame: Approximately 2.5 years after first subject bb2121 infused ]
    Is defined as time to start lenalidomide maintenance therapy post-bb2121 infusion

  6. Feasibility of initiating maintenance [ Time Frame: Approximately 2.5 years after first subject bb2121 infused ]
    Number of subjects starting the maintenance or on maintenance between D90 and D110

  7. Progression-free Survival (PFS) [ Time Frame: Approximately 2.5 years after first subject bb2121 infused ]
    Is defined as time from bb2121 infusion date to first documentation of PD, or death due to any cause, whichever occurs first.

  8. Overall Survival (OS) [ Time Frame: Approximately 2.5 years after first subject bb2121 infused ]
    Is defined as time from bb2121 infusion date to time of death due to any cause

  9. Pharmacokinetics - Cmax [ Time Frame: Approximately 2.5 years after first subject bb2121 infused ]
    Maximum transgene level

  10. Pharmacokinetics - Tmax [ Time Frame: Approximately 2.5 years after first subject bb2121 infused ]
    Time to peak transgene level

  11. Pharmacokinetics - AUC [ Time Frame: Approximately 2.5 years after first subject bb2121 infused ]
    Area under the curve of the transgene level



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subjects must satisfy all of the following criteria to be enrolled in the study:

  1. Subject is newly diagnosed and has symptomatic Multiple Myeloma (MM) prior to initiating induction anti-myeloma therapy
  2. Subject is ≥ 18 years of age at the time of initial diagnosis of MM
  3. Subject has measurable disease at initial diagnosis by

    • M-protein and/or
    • Light chain MM without measurable disease in the serum or urine
  4. Subject has high-risk MM at the time of initial diagnosis of MM per R-ISS Stage III as defined by IMWG:

    • ISS Stage III and cytogenetic abnormalities with t(4; 14) and/or del(17p); and/or t(14:16) by iFISH; or;
    • ISS Stage III and serum LDH > ULN
  5. Subject has Eastern Cooperative Oncology Group performance ≤ 1
  6. Subjects has received ≤ to 3 cycles of the following induction anti-myeloma therapy prior to enrollment:

    • Cycle 1: one of the following regimens (RVd, KRd, CyBorD, D-RVd and D-KRd)
    • Cycle 2 to Cycle 3: either KRd or RVd (Cycle 3 must be without dexamethasone)

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment: The presence of any of the following will exclude a subject from enrollment:

At initial diagnosis, screening and prior to initiation of induction therapy for MM:

  1. Subject has non-secretory MM

    During Screening:

  2. Subject received any treatments for MM other than up to 3 cycles of induction therapy per protocol
  3. Subject has any of the following laboratory abnormalities:

    1. Absolute neutrophil count < 1,000/μL
    2. Platelet count < 50,000 mm3
    3. Hemoglobin < 8 g/dL (< 4.9 mmol/L)
    4. Serum creatinine clearance < 45 mL/min
    5. Corrected serum calcium > 13.5 mg/dL (> 3.4 mmol/L)
    6. Serum aspartate aminotransferase or alanine aminotransferase > 2.5 × upper limit of normal
    7. Serum total bilirubin > 1.5 × ULN or > 3.0 mg/dL for subjects with documented Gilbert's syndrome
    8. INR or aPTT > 1.5 × ULN
  4. Subject has history or presence of clinically significant CNS pathology
  5. Subjects has high risk for developing deep vein thrombosis or pulmonary embolus and are unable or unwilling to undergo anti-thrombotic therapy
  6. Subject has peripheral neuropathy of > Grade 2 severity according to the NCI CTCAE Version 4.03 with bortezomib based induction regimen
  7. Subjects has moderate or severe pulmonary hypertension
  8. Subject has intolerance to components of induction regimen (KRd or RVd) or has any contraindication to one or the other drug
  9. Subject has not recovered from induction therapy-related toxicities (non-hematologic) to < grade 1 CTCAE at the time of screening
  10. Subject has prior history of deep vein thrombosis or pulmonary embolus (PE) within 6 months of starting study treatment
  11. Subject has cardiac conditions such as:

    1. Echocardiogram or multi gated acquisition assessment of left ventricular ejection fraction < 45%
    2. Subject has a history of clinically significant cardiovascular disease or clinically significant ECG abnormalities
  12. Subject has Pulmonary conditions such as:

    1. Subject has known chronic obstructive pulmonary with a forced expiratory vol in 1 sec 50% of predicted normal.
    2. Inadequate pulmonary function defined as oxygen saturation < 92 % on room air
  13. Subject needs ongoing treatment with chronic immunosuppressants
  14. Subject has history of primary immunodeficiency
  15. Subject is seropositive for human immunodeficiency virus, chronic or active hepatitis B or active hepatitis A or C

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04196491


Contacts
Layout table for location contacts
Contact: Associate Director Clinical Trial Disclosure 1-888-260-1599 clinicaltrialdisclosure@celgene.com

Locations
Layout table for location information
United States, Colorado
Colorado Blood Cancer Institute Recruiting
Denver, Colorado, United States, 80218
United States, Florida
Mayo Clinic - Jacksonville Recruiting
Jacksonville, Florida, United States, 32224
United States, Georgia
Winship Cancer Institute of Emory University Recruiting
Atlanta, Georgia, United States, 30322
United States, New Jersey
Hackensack University Medical Center Recruiting
Hackensack, New Jersey, United States, 07601
United States, Tennessee
Sarah Cannon Research Institute Center for Blood Cancers Recruiting
Nashville, Tennessee, United States, 37203
Sponsors and Collaborators
Celgene
Investigators
Layout table for investigator information
Study Director: Suresh Shelat, MD, PhD Celgene/BMS
Layout table for additonal information
Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT04196491    
Other Study ID Numbers: BB2121-MM-004
U1111-1243-5088 ( Other Identifier: WHO )
First Posted: December 12, 2019    Key Record Dates
Last Update Posted: September 16, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Information relating to our policy on data sharing and the process for requesting data can be found at the following link:

https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/

Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: See Plan Description
Access Criteria: See Plan Description
URL: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Celgene:
Multiple Myeloma
Newly diagnosed multiple myeloma
BB2121
KarMMa-4
Phase I
NDMM
High Risk
R-ISS III
KRd
RVd
Dara-KRd
Dara-RVd
CyBorD
BCMA
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Cyclophosphamide
Fludarabine
Lenalidomide
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors